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Purpose: Recently, cognitive variables such as negative and positive self-belief and thoughts 
have attracted much attention because they are associated with functional outcomes and quality 
of life (QOL). However, it is unclear how cognitive variables affect subjective and objective 
QOL. This study aimed to investigate the relationship of negative and positive self-belief and 
thoughts with subjective and objective QOL.
Participants and methods: Thirty-six people with schizophrenia participated in this study. 
Subjective and objective QOL were assessed with the Schizophrenia Quality of Life Scale 
(SQLS) and Quality of Life Scale (QLS), respectively. Neurocognitive function was assessed 
with the Brief Assessment of Cognition in Schizophrenia (BACS). Clinical symptoms were 
assessed with the Positive and Negative Syndrome Scale and Calgary Depression Scale for 
Schizophrenia. Side effects were assessed with the Drug-induced Extrapyramidal Symptoms 
Scale (DIEPSS). Negative and positive self-belief and thoughts were assessed with the Defeatist 
Performance Belief Scale and Automatic Thoughts Questionnaire-Revised. A generalized linear 
model was tested, with subjective and objective QOL as the response variable and symptoms, 
neurocognitive function, and cognitive variables that were significantly correlated with subjec-
tive and objective QOL as explanatory variables.
Results: In the schizophrenia group, the common objects score on the QLS was predicted 
by the composite BACS score, and the total QLS score was predicted by the DIEPSS score. 
Motivation and Energy, Psychosocial, and Symptoms and Side effects scores on the SQLS 
were predicted by depression and by negative automatic thought (NAT) and positive automatic 
thought (PAT).
Conclusion: Our results indicated that key targets for improving objective and subjective 
QOL in people with schizophrenia are side effects, neurocognitive function, depression, and 
NAT and PAT.
Keywords: defeatist performance belief, negative and positive automatic thoughts, subjective 
quality of life, objective quality of life, schizophrenia
Introduction
The goal of schizophrenia treatment has moved from “remission of symptoms” to 
“recovery in life.” In order to achieve recovery, it is necessary to identify the factors 
of functioning that lead to a good quality of life (QOL). QOL has been measured 
from two viewpoints. One is subjective QOL, which is rated by themselves, and the 
other is objective QOL, which is rated by observers.1 The concept of subjective QOL 
comprises well-being and satisfaction with life and that of objective QOL comprises 
daily life functioning and external resources.2,3 Furthermore, the correlation between 
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objective and subjective QOL is reported to be weak to 
moderate.4,5 To achieve “recovery in life,” we must consider 
both subjective and objective viewpoints to understand the 
target and effect of treatment.
Previous studies have shown that several clinical factors 
such as positive symptoms, negative symptoms, depressive 
symptoms, dose of antipsychotics, and lower daily activity 
are associated with low subjective QOL.4–7 In addition, 
clinical factors such as neurocognitive function, positive 
symptoms, negative symptoms, depressive symptoms, side 
effects, dose of antipsychotics, and duration of illness have 
been found to be associated with low objective QOL.1,4,5,8,9 
Together, these studies show that symptoms and neurocog-
nitive function affect both subjective and objective QOL.
Recently, cognitive variables such as defeatist perfor-
mance belief (DPB) have received much attention because 
they have been found to be associated with negative 
symptoms, functional outcomes, and QOL.10–13 DPB is a 
maladaptive belief (eg, “If you cannot do something well, 
there is little point in doing it at all”) that guides overgen-
eralized conclusion about one’s ability to perform a task.10 
Grant and Beck10 suggested that neurocognitive deficits 
could contribute to failure experiences and difficulties in 
daily life, which may lead to the development of DPB and 
negative appraisals. Furthermore, Rector et al14 suggested that 
these cognitive variables might contribute to the avoidance 
of activities of daily living. Chung et al15 showed that not 
only negative beliefs but also positive beliefs about oneself 
are necessary for recovery. Negative and positive apprais-
als related to beliefs are negative automatic thought (NAT) 
and positive automatic thought (PAT) regarding oneself, 
the future, and the world.16,17 NAT and PAT increase auto-
matically when people encounter negative and positive life 
events.17,18 Previous studies suggested that PAT (positive self-
statement) might contribute to social adaptation and QOL.19,20
Previous studies have studied how symptoms and neuro-
cognitive function influence subjective and objective QOL; 
however, it is still unclear how negative and positive self-
belief and thoughts affect them. In this study, we investigated 
the relationship of negative and positive self-thought with 
both subjective and objective QOL.
Methods
Participants
Thirty-six people with schizophrenia participated in this 
study, including 16 men and 20 women with a mean age 
(±SD) of 42.86±9.40 years. All of them were diagnosed 
with schizophrenia based on the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition criteria. At the 
time of study admission, they were clinically stable, as 
judged by a therapeutic psychiatrist after drug adjustment 
was completed. There was no remarkable change in their 
psychopathology during this study. The exclusion criteria 
were as follows: 1) past history or presence of any serious 
medical and neurological disorders that affect the brain or 
cognitive functioning, such as epilepsy, serious head injury, 
or brain tumor; 2) drug or alcohol abuse; and 3) active drug 
use in the past year.
Moreover, 37 demographically matched healthy controls 
were selected, including 17 men and 20 women. They were 
college students, hospital employees, or hospital employee’s 
acquaintances, with a mean age of 43.32±9.77 years. All 
participants provided written informed consent, and the 
study was approved by the institutional ethics committee 
of Tokushima University. This study was conducted in 
accordance with the Declaration of Helsinki.
Measures
Japanese adult reading Test (JarT)
We used the 25-item short version of the JART,21,22 which 
was validated to estimate the premorbid intellectual ability 
by assessing the ability of reading Chinese characters.22
Wechsler adult intelligence scale-iii (Wais-iii)
To estimate the present intellectual ability, we used the short 
version of the WAIS-III,23,24 which comprises Information 
and Matrix Reasoning25 and has good reliability and validity 
compared to the standard version of WAIS-III.26
Positive and negative symptoms
To assess positive and negative symptoms, we used the 
Positive and Negative Syndrome Scale (PANSS).27,28 Higher 
scores indicate a greater level of symptom severity.
Depression
To assess depression, we used the Calgary Depression Scale 
for Schizophrenia (CDSS).29,30 The CDSS was specifically 
developed to distinguish depressive symptoms from positive 
and negative symptoms or antipsychotic-induced adverse 
effects in people with schizophrenia.30 Higher scores indicate 
a greater level of depression.
side effects
To assess drug-induced extrapyramidal symptoms, we 
used the Drug-induced Extrapyramidal Symptoms Scale 
(DIEPSS).31 Higher scores indicate a greater level of extra-
pyramidal adverse effects.
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Neurocognitive function
To assess neurocognitive function, we used the Brief 
Assessment of Cognition in Schizophrenia (BACS).32,33 
The domains of neurocognitive function evaluated by the 
BACS include verbal memory, working memory, motor 
speed, verbal fluency, attention and speed of information 
processing, and executive function. A composite score is 
calculated by averaging the scores on these six standardized 
primary measures.32
DPB
To assess DPB, we used the Defeatist Performance Belief 
Scale (DPS), which is a subscale of the Dysfunctional Atti-
tudes Scale (DAS).17,34 The DPS contains 15 items assessing 
an individual’s tendency to overgeneralize past failures to 
expected future failure.10 Higher scores indicate a greater 
level of DPB. In this study, the DPS showed good inter-
nal consistency in people with schizophrenia and controls 
(α=0.79 and 0.86, respectively).
automatic thoughts
To assess automatic thoughts, we used the Automatic 
Thoughts Questionnaire-Revised (ATQ-R).17,35 This 40-item 
self-report instrument is designed to measure the frequency 
of occurrence of NATs (negative self-statements) and PATs 
(positive self-statements). Higher scores indicate a greater 
frequency of occurrence of NAT and PAT. The ATQ-R 
has a good reliability in Japanese people (α of NAT =0.95, 
α of PAT =0.82).36 Its construct validity was supported 
by its significant relationship with measures of depressive 
symptoms, eg, higher NAT was related to higher depression 
(Pearson’s r=0.72, P,0.01) and higher PAT was related to 
lower depression (Pearson’s r=-0.58, P,0.01).36
QOl
To assess subjective QOL, we used the Schizophrenia 
Quality of Life Scale (SQLS).37,38 It is a 30-item self-report 
questionnaire specific to people with schizophrenia. It com-
prises the following three scales: Psychosocial (PS), Moti-
vation and Energy (ME), and Symptoms and Side effects 
(SS). Lower scores indicate better level of subjective QOL. 
PS addresses various emotional problems, for example, 
feeling lonely, depressed, or hopeless. ME address various 
problems of motivation and activity, such as lacking the will 
to do things. SS address issues such as sleep disturbance and 
blurred vision, which can be caused by medication.
To assess objective QOL, we used the Quality of Life 
Scale (QLS).39,40 It is a 21-item tool comprising the following 
five scales: Interpersonal relationships, Instrumental roles, 
Intrapsychic foundations, Common objects and activities, 
and total score. Higher scores indicate better objective QOL. 
Interpersonal relationships address various aspects of inter-
personal and social experiences. Instrumental roles address 
the subjects’ roles of a worker, students, or housekeepers. 
Intrapsychic foundations address subjects’ sense of purpose 
and motivation. Common objects and activities address the 
possession of common objects and engagement in a range 
of regular activities.
statistical analyses
Data analysis was conducted using SPSS Statistics for 
Windows, Version 22.0, R version 3.3.3 (2017-03-06), and 
R-studio.41–43 The demographic indices were compared 
between people with schizophrenia and controls using 
unpaired Chi-squared test, independent t-test, and the Mann–
Whitney U test. For correlation analysis, Pearson’s correla-
tion coefficients and Spearman’s rank correlation coefficients 
were calculated to evaluate the relationship of symptoms and 
neurocognitive function with cognitive variables and QOL 
in people with schizophrenia, according to the normality of 
the distribution of the dependent variables. Here, we used the 
false discovery rate (FDR) correction to adjust for multiple 
testing and set the significant threshold as an FDR-adjusted 
P-value of 0.05. Finally, a generalized linear model (GLM) 
was tested with subjective and objective QOL as the response 
variable and symptoms, neurocognitive function, and cogni-
tive variables that had significant correlations with subjective 
and objective QOL as explanatory variables. The GLM is a 
flexible generalization of an ordinary linear regression that 
allows for response variables that have error distribution 
models other than a normal distribution. GLM is determined 
by two components (the distribution of the dependent variable 
and the link function). We used Gaussian and gamma distri-
butions according to the normality of the dependent variables. 
For the GLM analysis, we used the MASS, qcc, AER, and 
pscl package in R-studio.44–47
Results
The demographic indices and cognitive performances of 
people with schizophrenia and controls are summarized in 
Table 1. People with schizophrenia were shown to have lower 
education year, premorbid intelligence quotient, present 
intelligence quotient, verbal memory, working memory, 
motor speed, attention and speed of information processing, 
verbal fluency, executive function, interpersonal relation-
ships, instrumental role, intrapsychic foundation, common 
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objects and activities, and total QLS score than controls. 
On the other hand, people with schizophrenia were shown 
to have higher NAT, DPB, ME score, and PS score than 
controls. The composite BACS score of the schizophrenia 
group was -1.20±0.76.
Results of the Pearson’s correlation analyses and 
Spearman’s rank correlation coefficient analyses are shown 
in Tables 2 and 3. As shown in Table 2, higher verbal fluency 
score and the composite score of BACS were significantly 
related to higher common objects and activities score of 
QLS in the schizophrenia group. Fewer side effect and 
higher motor speed score and the composite BACS score 
and PAT score were significantly related to higher total 
QLS score. Furthermore, higher PAT score was significantly 
related to fewer ME score on the SQLS (Table 3). Higher 
depression and NAT were significantly related to higher PS 
score on the SQLS, and higher DPB and NAT were signifi-
cantly related to the SS score (Table 3). On the other hand, 
in the control group (data not shown in Tables 2 and 3), 
there was no significant correlation between self-thought 
and objective QOL. However, there were significant correla-
tions between self-thought and subjective QOL. DPB had a 
Table 1 Participants’ demographic data
 Schizophrenia Control Statistical value P-value Effect size
N (men/women) 36 (16/20) 37 (17/20) x2=0.02 P=0.90 Ø,0.01
age (years) 42.86 (9.40) 43.32 (9.77) t=-0.21 P=0.84 d=0.05
education (years) 14.03 (1.86) 15.16 (2.15) u=464.00 P=0.02 r=-0.28
Premorbid iQ (JarT) 98.72 (9.69) 109.51 (6.03) t=-5.70 P,0.01 d=1.34
iQ (Wais: Vocabulary, Matrix 
reasoning)
88.69 (15.66) 105.92 (14.11) t=-4.94 P,0.01 d=1.16
Duration of illness 16.04 (7.12)     
Dose of antipsychotics (mg/day) 444.67 (327.16)     
PaNss
Positive syndrome 13.14 (3.59)     
Negative syndrome 15.33 (4.14)     
cDss 3.33 (2.92)     
DiePss 1.47 (1.95)     
Bacs
Verbal memory 35.39 (12.57) 45.49 (8.91) u=353.00 P,0.01 r=-0.41
Working memory 16.58 (3.49) 21.11 (3.97) t=-5.17 P,0.01 d=1.21
Motor speed 67.67 (14.12) 81.03 (11.44) t=-4.45 P,0.01 d=1.04
attention and speed of 
information processing
51.47 (10.47) 66.70 (8.41) u=146.50 P,0.01 r=-0.67
Verbal fluency (total) 37.39 (10.06) 46.46 (9.12) t=-4.04 P,0.01 d=0.95
executive function 16.97 (2.30) 18.76 (1.83) u=356.00 P,0.01 r=-0.41
composite score -1.20 (0.76)     
aTQ-r
Negative automatic thought 67.64 (29.62) 46.08 (12.22) t=4.05 P,0.01 d=0.96
Positive automatic thought 18.19 (6.99) 19.92 (7.67) u=555.00 P=0.22 r=-0.14
DPs 41.50 (8.70) 35.24 (8.80) t=3.05 P,0.01 d=0.72
Qls
interpersonal relationship 24.31 (8.48) 40.19 (8.72) u=129.50 P,0.01 r=-0.69
instrumental role 14.89 (7.39) 21.89 (3.11) u=292.00 P,0.01 r=-0.50
intrapsychic foundations 24.50 (10.48) 37.35 (6.15) u=181.50 P,0.01 r=-0.63
common objects and 
activities
6.94 (1.41) 8.05 (1.31) u=412.00 P,0.01 r=-0.34
Total score 70.64 (22.54) 107.49 (15.68) u=111.00 P,0.01 r=-0.72
sQls
Me 13.25 (4.95) 10.92 (3.92) t=2.24 P=0.03 d=0.52
Ps 25.14 (12.74) 17.32 (7.91) t=3.14 P,0.01 d=0.74
ss 9.33 (9.21) 5.87 (4.98) u=514.50 P=0.09 r=-0.20
Note: Bold values indicate significant differences between two groups at the level of 0.05. 
Abbreviations: aTQ-r, automatic thoughts Questionnaire-revised; Bacs, Brief assessment of cognition in schizophrenia; cDss, calgary Depression scale for 
schizophrenia; DiePss, Drug-induced extrapyramidal symptoms scale; DPs, Defeatist Performance Belief scale; JarT, Japanese adult reading Test; Me, Motivation and 
energy; PaNss, Positive and Negative syndrome scale; Ps, Psychosocial; Qls, Quality of life scale; ss, symptoms and side effects; sQls, schizophrenia Quality of life scale; 
Wais, Wechsler adult intelligence scale.
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significant correlation with the PS score and the ME score 
(Pearson’s r=0.54, 0.43, P,0.01, respectively). NAT had a 
significant correlation with the PS score and the ME score 
(Pearson’s r=0.76, 0.61, P,0.01, respectively). PAT had 
a significant correlation with the ME score (Spearman’s 
rho r=-0.61, P,0.01). As with people with schizophrenia, 
self-thought was associated with subjective QOL in the 
control group.
Table 4 shows the results of the GLM analysis in the 
schizophrenia group. The common objects and activities 
score on the QLS was predicted by the composite BACS score 
(β=0.15, P=0.02). Total QLS score was predicted by side 
effects (β=-4.01, P=0.03). Furthermore, the ME score on 
the SQLS was predicted by PAT (β=-0.34, P,0.01); the PS 
score was predicted by NAT (β=0.21, P,0.01) and depres-
sion (β=1.51, P=0.03); and the SS score was predicted by 
NAT (β=0.01, P,0.01).
Discussion
We showed that people with schizophrenia have higher 
negative belief and thoughts than controls. Furthermore, the 
results of this study indicated that objective QOL was pre-
dicted by side effects and neurocognitive function, whereas 
subjective QOL was predicted by depression and PAT and 
NAT. Therefore, we suggested that the key targets of treat-
ment in people with schizophrenia to improve subjective and 
Table 3 relationship between subjective quality of life and clinical variables
 ME P-value PS P-value SS P-value
PaNss
Positive symptom 0.13 P=0.51 0.18 P=0.68 0.32 P=0.17
Negative symptom 0.35 P=0.11 0.03 P=0.95 -0.01 P=0.96
cDss
Depression 0.30 P=0.16 0.56 P,0.01 0.32 P=0.17
DiePss
side effect 0.17 P=0.41 -0.05 P=0.95 0.14 P=0.55
Bacs
Verbal memory -0.01 P=0.98 0.11 P=0.95 -0.10 P=0.68
Working memory -0.26 P=0.20 -0.16 P=0.68 -0.26 P=0.19
Motor speed -0.36 P=0.11 -0.31 P=0.25 -0.22 P=0.27
attention and speed of 
information processing
-0.28 P=0.18 -0.13 P=0.80 -0.27 P=0.19
Verbal fluency (total) -0.22 P=0.28 -0.10 P=0.80 -0.27 P=0.19
executive function 0.09 P=0.67 -0.11 P=0.80 -0.02 P=0.96
composite score -0.28 P=0.18 -0.19 P=0.68 -0.29 P=0.19
DPs
Defeatist performance belief 0.34 P=0.11 0.34 P=0.19 0.48 P=0.02
aTQ-r
Negative automatic thought 0.38 P=0.11 0.65 P,0.01 0.55 P,0.01
Positive automatic thought -0.51 P=0.03 -0.03 P=0.95 -0.32 P=0.17
Notes: Bold values indicate significant correlations at the level of 0.05.
Abbreviations: aTQ-r, automatic Thoughts Questionnaire-revised; Bacs, Brief assessment of cognition in schizophrenia; cDss, calgary Depression scale for 
schizophrenia; DiePss, Drug-induced extrapyramidal symptoms scale; DPs, Defeatist Performance Belief scale; Me, Motivation and energy; PaNss, Positive and Negative 
syndrome scale; Ps, Psychosocial; ss, symptoms and side effects.
Table 4 results of the general linear modeling analysis
Response variable Explanatory variable Estimate (β) P-value GLM used
Qls
common objects composite score 0.15 P=0.02 gamma
Total score side effect -4.01 P=0.03 gaussian
sQls     
Me PaT -0.34 P,0.01 gaussian
Ps NaT 0.21 P,0.01 gaussian
Depression 1.51 P=0.03  
ss NaT 0.01 P,0.01 gamma
Abbreviations: glM, generalized linear model; Me, Motivation and energy; NaT, negative automatic thought; PaT, positive automatic thought; Ps, Psychosocial; Qls, 
Quality of life scale; sQls, schizophrenia Quality of life scale; ss, symptoms and side effects.
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objective QOL are side effect, depression, neurocognitive 
function, and negative and positive self-thoughts.
Previous studies indicated that people with schizophrenia 
have higher DPB than controls.10–12 In addition, Hill et al48 
showed that people with schizophrenia have higher NAT 
than controls. We confirmed these findings in Japanese 
people with schizophrenia. On the other hand, PAT did not 
differ significantly between the people with schizophrenia 
and controls. As far as we know, this is the first study to 
compare PATs between people with schizophrenia and 
controls. However, some previous studies have compared 
positive self-cognition between people with schizophrenia 
and controls, and they reported no differences between the 
two groups.49,50 In addition, Trémeau et al51 indicated that 
affective and cognitive processes involved in the anticipa-
tion and experience for positive affective events showed no 
deficit in people with schizophrenia. Our results are in line 
with previous studies and suggest that it is possible for stable 
people with schizophrenia to retain positive self-thought 
while having strong negative self-belief and thoughts.
As for the relationship of objective QOL and clinical 
variables with neurocognitive function and self-thought, the 
results of this study were consistent with those of previous 
studies that showed that neurocognitive function and side 
effects affect objective QOL.1,8,9 This result suggested that 
improvement of neurocognitive function and reduction of 
side effects might help improve objective QOL in people with 
schizophrenia. Previous studies showed a small correlation 
between DPB and objective QOL.11,12 However, this study did 
not find the significant relationship between DPB and objec-
tive QOL. This inconsistency might be caused by a difference 
in the measurement of QOL and the low statistical power 
due to the small number of participants. As for automatic 
thought, this study showed that automatic thought did not 
predict objective QOL. As far as we know, this is the first 
study that investigated the relationship between automatic 
thought and objective QOL in people with schizophrenia; 
however, further studies are needed to confirm these findings.
As for the relationship of subjective QOL and clinical 
variables with neurocognitive function and self-thought, 
the results of this study were consistent with those of 
previous studies that reported that depression affects sub-
jective QOL.4–7 In addition, this study showed that NAT 
predicts higher feelings of loneliness. On the other hand, 
PAT predicted higher motivation and activities. Previous 
studies indicated that lower NAT and higher PAT have a 
significant relationship with subjective life satisfaction, 
social adaptation, and QOL in healthy subjects19,52 and people 
with depression.20 This study suggested that both PAT and 
NAT might be important for improving subjective QOL for 
people with schizophrenia as well. However, contrary to the 
expectation, DPB did not predict objective and subjective 
QOL in this study. Grant and Beck10 indicated that DPB 
was significantly correlated with objective QOL (Pearson’s 
r=-0.45, P,0.01). In addition, Campellone et al13 conducted 
a meta-analytic review and found a small effect size for the 
relationship of DPB and functional outcomes such as QOL 
and life skills. This inconsistency might be caused by a dif-
ference in the measurement of QOL and statistical methods. 
Furthermore, previous studies indicated that automatic 
thought strongly predicts depression than belief.48,53 Above 
all, automatic thought may affect the current state of mood 
and motivation rather than long-lasting beliefs. Therefore, 
automatic thought, rather than beliefs, might have more effect 
on subjective QOL, including motivation and emotional 
problems. However, few studies have examined the relation-
ship among DPB, automatic thought, and QOL in people with 
schizophrenia. Thus, future studies need to further consider 
the relationship among these variables.
Conclusion
This study indicated that improving self-thought is an impor-
tant target of treatment, in order to achieve recovery and 
improve the QOL of people with schizophrenia. Therefore, 
our findings may provide further evidence for the importance 
of PS treatment (eg, cognitive remediation therapy and cog-
nitive behavior therapy) combined with pharmacotherapy.
This study has some limitations. First, the sample size 
was relatively small. Second, the participants showed rela-
tively mild symptoms. Therefore, our results may not reflect 
the characteristics of all people with schizophrenia. Third, 
medications may have had an influence on our findings. 
Some of our people with schizophrenia might have depressed 
mood due to the side effects of antipsychotics. However, it 
is difficult to separate general depression from that caused 
by the side effects of antipsychotics. Fourth, we did not use 
structural interview for assessing control subjects. However, 
controls were evaluated with brief interviews to confirm the 
absence of schizophrenia and had no history of neurological 
or psychiatric disorders or any first-degree relatives with psy-
chotic episodes. Future studies need to employ more detailed 
assessments of the mental status of healthy controls. Fifth, 
DPS that we used in this study has no significant correlation 
with negative symptoms (Pearson’s r=0.14, P=0.41). Meta-
analysis indicated that the effect size is 0.25 between DPB 
and negative symptoms. This inconsistency might be caused 
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by a difference in the measurement of negative symptoms 
and the low statistical power due to the small number of 
participants. Future study needs to clarify the relationship 
between DPB and negative symptoms in a larger sample of 
Japanese people with schizophrenia.
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